Skip to content
Menu

Guggenheim Maintains Buy on Eloxx Pharma, Lowers Price Target to $40

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Guggenheim analyst Vamil Divan maintains Eloxx Pharma (NASDAQ:ELOX) with a Buy and lowers the price target from $43 to $40.

Guggenheim analyst Vamil Divan maintains Eloxx Pharma (NASDAQ:ELOX) with a Buy and lowers the price target from $43 to $40.

Read at benzinga.com

← All stock news